NeOnc Technologies CEO Amir Heshmatpour increased his shareholding by buying 80,000 shares as the company prepares for a key FDA meeting in January 2027. The meeting will discuss a potential accelerated approval pathway for NEO100, an investigational brain cancer therapy, and the design of a Phase 3 trial. Upcoming presentations at the Society for Neuro-Oncology meeting will provide updated clinical data. These developments are critical as NeOnc seeks regulatory clarity and progress toward advanced clinical trials for NEO100, aiming to improve treatment for aggressive brain cancers.
NeOnc Technologies insider buying activity is noted here for context. For readers following the Health sector, here is Pluang's market snapshot as of Nov 12, 2026 20:12 WIB: Of 150 priced Health-sector US stocks tradable on Pluang, 82 rose and 64 fell today. Notable movers include RXRX at USD 3.46 with a 1-day change of -3.62% and 100% buy order activity, MRVI at USD 7.94 up 3.12% with 55% sell order activity, and HRTX at USD 0.35 down 2.56% with 85% buy order activity. The most notable figure is RXRX's 100% buy order activity on Pluang.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
